Systemic disease associations and management of pyoderma gangrenosum: a single-center retrospective case series
European Journal of Medical Case Reports · 21.06.2026 · 10 (7) · 218-222
DOI: 10.24911/ejmcr.9-2648 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Medical Case Reports, online erschienen am 19.06.2026. Verfasst von Ilyas El Kassimi und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis frequently associated with systemic inflammatory diseases. We aimed to describe systemic disease associations, management strategies, and outcomes of PG managed in internal
medicine.
Settings: Single-center retrospective case series conducted in an internal medicine department between January 2021 and December 2025.
Methods
We retrospectively reviewed all eligible patients treated for PG in our department during the study period. Diagnosis was based on clinicopathological assessment after exclusion of major mimickers; the Delphi consensus criteria were not formally applied because their individual components were not consistently documented in the retrospective records. Demographic, clinical, histological, treatment, and outcome data were extracted from medical records.
Results
Ten patients (five women; median age 40 years, range 19-58) were included. Ulcerative PG predominated (6/10), while four patients had pustular PG; lesions mainly involved the lower limbs, and pathergy was observed in five patients. An associated systemic disease was identified in eight patients, including Behçet disease, inflammatory bowel disease, systemic sclerosis, antineutrophil cytoplasmic antibody-associated vasculitis, systemic lupus erythematosus, and Takayasu arteritis. All patients received systemic corticosteroids; additional immunosuppressants or anti-tumor necrosis factor-alpha therapy were used as steroidsparing treatment and/or to control active associated systemic disease. Six patients achieved complete healing without relapse, whereas four experienced at least one relapse during chart-documented follow-up.
Conclusion
In internal medicine practice, PG is commonly linked to systemic inflammatory diseases, supporting a structured, clinically guided systemic work-up. Systemic corticosteroids remain first-line therapy, while immunosuppressants and targeted biologics are valuable steroid-sparing options when disease is refractory or coexists with active systemic inflammation.
Zitieren
APA
Kassimi, I. E., Rkiouak, A., Sahel, N., Zaizaa, M., Bougrini, Z. E., Talamoussa, B., & Sekkach, Y. (2026). Systemic disease associations and management of pyoderma gangrenosum: a single-center retrospective case series. European Journal of Medical Case Reports, 10(7), 218-222. https://doi.org/10.24911/ejmcr.9-2648
Vancouver
Kassimi IE, Rkiouak A, Sahel N, Zaizaa M, Bougrini ZE, Talamoussa B, et al. Systemic disease associations and management of pyoderma gangrenosum: a single-center retrospective case series. European Journal of Medical Case Reports. 2026;10(7):218-222. doi:10.24911/ejmcr.9-2648
BibTeX
@article{Kassimi2026,
author = {Kassimi, Ilyas El and Rkiouak, Adil and Sahel, Nawal and Zaizaa, Meryem and Bougrini, Zineb El and Talamoussa, Bilal and Sekkach, Youssef},
title = {Systemic disease associations and management of pyoderma gangrenosum: a single-center retrospective case series},
journal = {European Journal of Medical Case Reports},
year = {2026},
volume = {10},
number = {7},
pages = {218--222},
doi = {10.24911/ejmcr.9-2648}
}
EUVIMED